The dynamic roles of TGF‐β in cancer
Tóm tắt
The transforming growth factor‐β (TGF‐β) signalling pathway plays a critical and dual role in the progression of human cancer. During the early phase of tumour progression, TGF‐β acts as a tumour suppressor, exemplified by deletions or mutations in the core components of the TGF‐β signalling pathway. On the contrary, TGF‐β also promotes processes that support tumour progression such as tumour cell invasion, dissemination, and immune evasion. Consequently, the functional outcome of the TGF‐β response is strongly context‐dependent including cell, tissue, and cancer type. In this review, we describe the molecular signalling pathways employed by TGF‐β in cancer and how these, when perturbed, may lead to the development of cancer. Concomitantly with our increased appreciation of the molecular mechanisms that govern TGF‐β signalling, the potential to therapeutically target specific oncogenic sub‐arms of the TGF‐β pathway increases. Indeed, clinical trials with systemic TGF‐β signalling inhibitors for treatment of cancer patients have been initiated. However, considering the important role of TGF‐β in cardiovascular and many other tissues, careful screening of patients is warranted to minimize unwanted on‐target side effects. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Từ khóa
Tài liệu tham khảo
Friedman E, 1995, High levels of transforming growth factor β1 correlate with disease progression in human colon cancer, Cancer Epidemiol Biomarkers Prev, 4, 549
Dalal BI, 1993, Immunocytochemical localization of secreted transforming growth factor‐β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma, Am J Pathol, 143, 381
Picon A, 1998, A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1, Cancer Epidemiol Biomarkers Prev, 7, 497
Grady WM, 1999, Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers, Cancer Res, 59, 320
Wang D, 2000, Analysis of specific gene mutations in the transforming growth factor‐β signal transduction pathway in human ovarian cancer, Cancer Res, 60, 4507
Goggins M, 1998, Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas, Cancer Res, 58, 5329
Chen T, 1998, Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer, Cancer Res, 58, 4805
Sakakura T, 1981, Accelerated mammary cancer development by fetal salivary mesenchyma isografted to adult mouse mammary epithelium, J Natl Cancer Inst, 66, 953
Myeroff LL, 1995, A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability, Cancer Res, 55, 5545
Parsons R, 1995, Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer, Cancer Res, 55, 5548
Schutte M, 1996, DPC4 gene in various tumor types, Cancer Res, 56, 2527
Takenoshita S, 1998, Absence of mutations in the analysis of coding sequences of the entire transforming growth factor‐β type II receptor gene in sporadic human breast cancers, Oncol Rep, 5, 367
Hoot KE, 2008, Keratinocyte‐specific Smad2 ablation results in increased epithelial–mesenchymal transition during skin cancer formation and progression, J Clin Invest, 118, 2722
Rowland‐Goldsmith MA, 2002, Soluble type II transforming growth factor‐β receptor attenuates expression of metastasis‐associated genes and suppresses pancreatic cancer cell metastasis, Mol Cancer Ther, 1, 161
Matsuyama S, 2003, SB‐431542 and Gleevec inhibit transforming growth factor‐β‐induced proliferation of human osteosarcoma cells, Cancer Res, 63, 7791